Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Genitourinary 2Dermatologic 1

Conditions

Carcinoma, Hepatocellular 147Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 28Cholangiocarcinoma 26Endometrial Neoplasms 19Thyroid Neoplasms 17Liver Neoplasms 17Melanoma 15Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 13Recurrence 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma 4Adenocarcinoma 4Thyroid Cancer, Papillary 3

Interventions

Temozolomide 163Radiosurgery 128Radiotherapy 106Bevacizumab 97Magnetic Resonance Spectroscopy 74Carboplatin 48Surgical Procedures, Operative 35Etoposide 34pembrolizumab 33Radiation 33Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Brain Neoplasms × lenvatinib × Clear all
NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Recruiting
104 enrolled
CNS

Brain Neoplasms, Neoplasms

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡